Immune cell - produced ROS and their impact on tumor growth and metastasis

• Published in: Redox biology Vol. 42; p. 101891
• Main Authors: Kennel, Kilian B., Greten, Florian R.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01-06-2021; Elsevier
• Subjects: from the Special Issue on Redox Modulation of Cancer Heterogeneity, Therapeutic Resistance and Immunotherapy Efficacy; Edited by Dr. Anita Hjelmeland; Immune cells; ROS; TME; Immune cells; TME; ROS
• ISSN: 2213-2317; 2213-2317
• DOI: 10.1016/j.redox.2021.101891

Reactive oxygen species (ROS) are derivatives of molecular oxygen (O2) involved in various physiological and pathological processes. In immune cells, ROS are mediators of pivotal functions such as phagocytosis, antigen presentation and recognition, cytolysis as well as phenotypical differentiation. Furthermore, ROS exert immunosuppressive effects on T and natural killer (NK) cells which is of particular importance in the so-called “tumor microenvironment” (TME) of solid tumors. This term describes the heterogenous group of non-malignant cells including tumor-associated fibroblasts and immune cells, vascular cells, bacteria etc. by which cancer cells are surrounded and with whom they engage in functional crosstalk. Importantly, pharmacological targeting of the TME and, specifically, tumor-associated immune cells utilizing immune checkpoint inhibitors - monoclonal antibodies that mitigate immunosuppression - turned out to be a major breakthrough in the treatment of malignant tumors. In this review, we aim to give an overview of the role that ROS produced in tumor-associated immune cells play during initiation, progression and metastatic outgrowth of solid cancers. Finally, we summarize findings on how ROS in the TME could be targeted therapeutically to increase the efficacy of cancer immunotherapy and discuss factors determining therapeutic success of redox modulation in tumors.